Erratum: Responsible implementation of expanded carrier screening (European Journal of Human Genetics (2016) 24 (e1-e12) DOI: 10.1038/ejhg.2015.271);Responsible implementation of expanded carrier screening

European Journal of Human Genetics

Volumn 24, Issue 6, 2016, Pages e1-e12

  Henneman, Lidewij ^a   Borry, Pascal ^b   Chokoshvili, Davit ^b,c   Cornel, Martina C ^a   Van El, Carla G ^a   Forzano, Francesca ^d   Hall, Alison ^e   Howard, Heidi C ^f   Janssens, Sandra ^c   Kayserili, Hülya ^g   Lakeman, Phillis ^h   Lucassen, Anneke ⁱ   Metcalfe, Sylvia A ^j   Vidmar, Lovro ^k   De Wert, Guido ^l   Dondorp, Wybo J ^l   Peterlin, Borut ^k  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d GALLIERA HOSPITAL   (Italy)

^e PHG FOUNDATION   (United Kingdom)

^f UPPSALA UNIVERSITY   (Sweden)

^g KOÇ UNIVERSITY   (Turkey)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^l MAASTRICHT UNIVERSITY   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATTITUDE; DECISION MAKING; FAMILY HISTORY; GENETIC SCREENING; HEALTH CARE PERSONNEL; HETEROZYGOTE; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; MEDICAL SOCIETY; MIDWIFE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCREENING TEST; ETHICS; EUROPE; GENETIC COUNSELING; MEDICAL GENETICS; ORGANIZATION AND MANAGEMENT; PSYCHOLOGY; STANDARDS;

DECISION MAKING; EUROPE; GENETIC COUNSELING; GENETIC TESTING; GENETICS, MEDICAL; HETEROZYGOTE; HUMANS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 84961226192     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2017.159     Document Type: Erratum

References (121)

1. UNSCEAR (United Nations Scientific Committee on the Effects of Atomic Radiation): Hereditary effects of radiation. United Nations: New York, NY, USA, 2001
2. Sankaranarayanan K. Ionizing radiation and genetic risks IX. Estimates of the frequencies of mendelian diseases and spontaneous mutation rates in human populations: a 1998 perspective. Mutat Res 1998; 411: 129-178
3. Ropers HH. On the future of genetic risk assessment. J Community Genet 2012; 3: 229-236
4. Morris JK, Law MR, Wald NJ. Is cascade testing a sensible method of screening a population for autosomal recessive disorders? Am J Med Genet A 2004; 128A: 271-275
5. Henneman L, Borry P, Chokoshvili D, et al. Responsible implementation of expanded carrier screening: Summary and recommendations of the European Society of Human Genetics. Eur J Hum Genet 2016; 24: 781-783
6. Castellani C, Macek Jr M, Cassiman JJ, et al. Benchmarks for cystic fibrosis carrier screening: a European consensus document. J Cyst Fibros 2010; 9: 165-178
7. Castellani C, Massie J. Newborn screening and carrier screening for cystic fibrosis: alternative or complementary? Eur Respir J 2014; 43: 20-23
8. Rigter T, Henneman L, Kristoffersson U, et al. Reflecting on earlier experiences with unsolicited findings: points to consider for next-generation sequencing and informed consent in diagnostics. Hum Mutat 2013; 34: 1322-1328
9. De Wert G, Dondorp W, Knoppers B. Preconception care and genetic risk: ethical issues. J Community Genet 2012; 3: 221-228
10. Kaback MM. Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. Eur J Pediatr 2000; 159(Suppl 3): S192-S195
11. Edwards JG, Feldman G, Goldberg J, et al. Expanded carrier screening in reproductive medicine-points to consider: a joint statement of the american college of medical genetics and genomics, american college of obstetricians and gynecologists, national society of genetic counselors, perinatal quality foundation, and society for maternalfetal medicine. Obstet Gynecol 2015; 125: 653-662
12. Andermann A, Blancquaert I, Beauchamp S, Dery V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008; 86: 317-319
13. Nuffield Council on Bioethics: Genetic Screening. Ethical Issues. Nuffield Council on Bioethics: London, UK, 1993
14. Health Council of the Netherlands: Committee Genetic Screening: Genetic Screening. Health Council: The Hague, The Netherlands, 1994, Report No. 1994: 22E
15. Godard B, Ten Kate L, Evers-Kiebooms G, Ayme S. Population genetic screening programmes: principles, techniques, practices, and policies. Eur J Hum Genet 2003; 11(Suppl 2): S49-S87
16. Human Genetics Commission: Increasing Options, Informing Choice: A Report on Preconception Genetic Testing and Screening. Human Genetics Commission: London, UK, 2011
17. Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med 2013; 15: 482-483
18. Janssens S, De Paepe A, Borry P. Attitudes of health care professionals toward carrier screening for cystic fibrosis. A review of the literature. J Community Genet 2014; 5: 13-29
19. Ioannou L, Massie J, Lewis S, et al. Evaluation of a multi-disease carrier screening programme in Ashkenazi Jewish high schools. Clin Genet 2010; 78: 21-31
20. Darcy D, Tian L, Taylor J, Schrijver I. Cystic fibrosis carrier screening in obstetric clinical practice: knowledge, practices, and barriers, a decade after publication of screening guidelines. Genet Test Mol Biomarkers 2011; 15: 517-523
21. Morgan MA, Driscoll DA, Mennuti MT, Schulkin J. Practice patterns of obstetriciangynecologists regarding preconception and prenatal screening for cystic fibrosis. Genet Med 2004; 6: 450-455
22. Poppelaars FA, Henneman L, Ader HJ, et al. How should preconceptional cystic fibrosis carrier screening be provided? Opinions of potential providers and the target population. Community Genet 2003; 6: 157-165
23. Qureshi N, Armstrong S, Modell B. GPs opinions of their role in prenatal genetic services: a cross-sectional survey. Fam Pract 2006; 23: 106-110
24. Poppelaars FA, Van Der Wal G, Braspenning JC, et al. Possibilities and barriers in the implementation of a preconceptional screening programme for cystic fibrosis carriers: a focus group study. Public Health 2003; 117: 396-403
25. McClaren BJ, Delatycki MB, Collins V, Metcalfe SA, Aitken M: It is not in my world: an exploration of attitudes and influences associated with cystic fibrosis carrier screening. Eur J Hum Genet 2008; 16: 435-444
26. Stark Z, Massie J, McClaren B, et al. Current practice and attitudes of Australian obstetricians toward population-based carrier screening for inherited conditions. Twin Res Hum Genet 2013; 16: 601-607
27. Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for betathalassaemia: a review of international practice. Eur J Hum Genet 2010; 18: 1077-1083
28. Jans SM, De Jonge A, Henneman L, Cornel MC, Lagro-Janssen AL. Attitudes of general practitioners and midwives towards ethnicity-based haemoglobinopathy-carrier screening. Eur J Hum Genet 2012; 20: 1112-1117
29. Modell B, Petrou M, Layton M, et al. Audit of prenatal diagnosis for haemoglobin disorders in the United Kingdom: the first 20 years. Br Med J 1997; 315: 779-784
30. Benn P, Chapman AR, Erickson K, et al. Obstetricians and gynecologists practice and opinions of expanded carrier testing and noninvasive prenatal testing. Prenat Diagn 2014; 34: 145-152
31. Metcalfe SA. Carrier screening in preconception consultation in primary care. J Community Genet 2012; 3: 193-203
32. Cho D, McGowan ML, Metcalfe J, Sharp RR. Expanded carrier screening in reproductive healthcare: perspectives from genetics professionals. Hum Reprod 2013; 28: 1725-1730
33. Ready K, Haque IS, Srinivasan BS, Marshall JR. Knowledge and attitudes regarding expanded genetic carrier screening among women s healthcare providers. Fertil Steril 2012; 97: 407-413
34. Stoll K, Resta R. Considering the cost of expanded carrier screening panels. Genet Med 2013; 15: 318-319
35. Ioannou L, McClaren BJ, Massie J, et al. Population-based carrier screening for cystic fibrosis: a systematic review of 23 years of research. Genet Med 2014; 16: 207-216
36. Rowley PT, Loader S, Levenkron JC. Cystic fibrosis carrier population screening: a review. Genet Test 1997; 1: 53-59
37. Chen LS, Goodson P. Factors affecting decisions to accept or decline cystic fibrosis carrier testing/screening: a theory-guided systematic review. Genet Med 2007; 9: 442-450
38. Conway SP, Allenby K, Pond MN. Patient and parental attitudes toward genetic screening and its implications at an adult cystic fibrosis centre. Clin Genet 1994; 45: 308-312; e-pub ahead of print 29 July 2015; doi: 10.1038/ejhg.2015.160
39. Janssens S, Chokoshvilli D, Binst C, et al. Attitudes of cystic fibrosis patients and parents toward carrier screening and related reproductive issues. Eur J Hum Genet 2016; 24: 506-512
40. Maxwell SJ, Kyne G, Molster C, Barker NM, Ormsby J, O Leary P. Perceptions of population cystic fibrosis prenatal and preconception carrier screening among individuals with cystic fibrosis and their family members. Genet Test Mol Biomarkers 2011; 15: 159-164
41. Clarke AJ. Genetic testing and genomic screening. In. Kumar D, Eng C (eds): Genomic Medicine: Principles and Practice, 2nd edn Oxford University Press: Oxford, UK, 2014, pp 224-225
42. Falik-Zaccai TC, Kfir N, Frenkel P, et al. Population screening in a Druze community: the challenge and the reward. Genet Med 2008; 10: 903-909
43. Basel-Vanagaite L, Taub E, Drasinover V, et al. Genetic carrier screening for spinal muscular atrophy and spinal muscular atrophy with respiratory distress 1 in an isolated population in Israel. Genet Test 2008; 12: 53-56
44. Zlotogora J, Carmi R, Lev B, Shalev SA. A targeted population carrier screening program for severe and frequent genetic diseases in Israel. Eur J Hum Genet 2008; 17: 591-597
45. Mathijssen IB, Henneman L, Van Eeten-Nijman JM, et al. Targeted carrier screening for four recessive disorders: high detection rate within a founder population. Eur J Med Genet 2015; 58: 123-128
46. Ekstein J, Katzenstein H. The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease. Adv Genet 2001; 44: 297-310
47. Frumkin A, Raz AE, Plesser-Duvdevani M, Lieberman S: The Most Important Test You ll Ever Take ?: attitudes toward confidential carrier matching and open individual testing among modern-religious Jews in Israel. Soc Sci Med 2011; 73: 1741-1747
48. Gason AA, Metcalfe SA, Delatycki MB, et al. Tay Sachs disease carrier screening in schools: educational alternatives and cheekbrush sampling. Genet Med 2005; 7: 626-632
49. Barlow-Stewart K, Burnett L, Proos A, et al. A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students. J Med Genet 2003; 40: 45
50. Leib JR, Gollust SE, Hull SC, Wilfond BS. Carrier screening panels for Ashkenazi Jews: is more better? Genet Med 2005; 7: 185-190
51. Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ, Kornreich R. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat 2010; 31: 1240-1250
52. Hall J, Fiebig DG, King MT, Hossain I, Louviere JJ. What influences participation in genetic carrier testing?: results from a discrete choice experiment. J Health Econom 2006; 25: 520-537
53. Borry P, Clarke A, Dierickx K. Carrier screening: look before you leap: carrier screening for type 1 Gaucher disease: difficult questions. Eur J Hum Genet 2007; 16: 139-140
54. Zuckerman S, Lahad A, Shmueli A. Carrier screening for gaucher disease: Lessons for low-penetrance, treatable diseases. JAMA 2007; 298: 1281-1290
55. Holtkamp KC, Van Maarle MC, Schouten MJ, Dondorp WJ, Lakeman P, Henneman L. Do people from the Jewish community prefer ancestry-based or pan-ethnic expanded carrier screening? Eur J Hum Genet 2016; 24: 171-177
56. Cao A, Rosatelli MC, Monni G, Galanello R. Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am 2002; 29: 305-vii
57. Van Elderen T, Mutlu D, Karstanje J, Passchier J, Tibben A, Duivenvoorden HJ. Turkish female immigrants intentions to participate in preconception carrier screening for hemoglobinopathies in the Netherlands: an empirical study. Public Health Genomics 2010; 13: 415-423
58. Van Der Pal SM, Van Kesteren NM, Van Wouwe JP, Van Dommelen P, Detmar SB. The attitudes and intention to participate in hemoglobinopathy carrier screening in The Netherlands among individuals from Turkish, Moroccan, and Surinamese descent. J Environ Public Health 2013; 2013: 374831
59. Ahmed S, Green JM, Hewison J. Attitudes towards prenatal diagnosis and termination of pregnancy for thalassaemia in pregnant Pakistani women in the North of England. Prenat Diagn 2006; 26: 248-257
60. Gitsels-van Der Wal JT, Mannien J, Ghaly MM, Verhoeven PS, Hutton EK, Reinders HS. The role of religion in decision-making on antenatal screening of congenital anomalies: a qualitative study amongst Muslim Turkish origin immigrants. Midwifery 2014; 30: 297-302
61. Giordano PC, Dihal AA, Harteveld CL. Estimating the attitude of immigrants toward primary prevention of the hemoglobinopathies. Prenat Diagn 2005; 25: 885-893
62. Lakeman P, Plass AM, Henneman L, Bezemer PD, Cornel MC, Ten Kate LP. Preconceptional ancestry-based carrier couple screening for cystic fibrosis and haemoglobinopathies: what determines the intention to participate or not and actual participation? Eur J Hum Genet 2009; 17: 999-1009
63. Prior TW, Snyder PJ, Rink BD, et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A 2010; 152A: 1608-1616
64. Martyn M, Anderson V, Archibald A, et al. Offering fragile X syndrome carrier screening: a prospective mixed-methods observational study comparing carrier screening of pregnant and non-pregnant women in the general population. BMJ Open 2013; 3: e003660
65. Archibald AD, Jaques AM, Wake S, Collins VR, Cohen J, Metcalfe SA: It s something I need to consider : Decisions about carrier screening for fragile X syndrome in a population of non-pregnant women. Am J Med Genet 2009; 149: 2731-2738
66. Fanos JH, Spangner KA, Musci TJ. Attitudes toward prenatal screening and testing for Fragile X. Genet Med 2006; 8: 129-133
67. Ames AG, Metcalfe SA, Dalton AA, Duncan RE, Emery J. Measuring informed choice in population-based reproductive genetic screening: a systematic review. Eur J Hum Genet 2015; 23: 8-21
68. Clayton EW, Hannig VL, Pfotenhauer JP, Parker RA, Campbell PW III, Phillips JA III. Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening. Am J Hum Genet 1996; 58: 617-627
69. Henneman L, Bramsen I, Van Kempen L, et al. Offering preconceptional cystic fibrosis carrier couple screening in the absence of established preconceptional care services. Community Genet 2003; 6: 5-13
70. Henneman L, Poppelaars FA, Ten Kate LP. Evaluation of cystic fibrosis carrier screening programs according to genetic screening criteria. Genet Med 2002; 4: 241-249
71. Bekker H, Modell M, Denniss G, et al. Uptake of cystic fibrosis testing in primary care: supply push or demand pull? BMJ 1993; 306: 1584-1586
72. Ahmad WI, Atkin K. Primary care and haemoglobin disorders: a study of families and professionals. Crit Public Health 2000; 10: 41-53
73. Dormandy E, Gulliford M, Bryan S, et al. Effectiveness of earlier antenatal screening for sickle cell disease and thalassaemia in primary care: cluster randomised trial. Br Med J 2010; 341: c5132
74. Van Agt HM, Korfage IJ, Essink-Bot ML. Interventions to enhance informed choices among invitees of screening programmes-A systematic review. Eur J Public Health 2014; 24: 789-801
75. Canatan D, Aydinok Y, Kilinc Y, et al. National thalassemia prevention campaign: the talotir project. Turk J Haematol 2013; 30: 91-92
76. Canatan D, Kose MR, Ustundag M, Haznedaroglu D, Ozbas S. Hemoglobinopathy control program in Turkey. Community Genet 2006; 9: 124-126
77. Saffi M, Howard N. Exploring the effectiveness of mandatory premarital screening and genetic counselling programmes for beta-thalassaemia in the Middle East: a scoping review. Publ Health Genomics 2015; 18: 193-203
78. Karimi M, Jamalian N, Yarmohammadi H, Askarnejad A, Afrasiabi A, Hashemi A. Premarital screening for beta-thalassaemia in Southern Iran: options for improving the programme. J Med Screen 2007; 14: 62-66
79. Alswaidi FM, O Brien SJ. Premarital screening programmes for haemoglobinopathies, HIV and hepatitis viruses: review and factors affecting their success. J Med Screen 2009; 16: 22-28
80. Srinivasan BS, Evans EA, Flannick J, et al. A universal carrier test for the long tail of Mendelian disease. Reprod Biomed Online 2010; 21: 537-551
81. Bell CJ, Dinwiddie DL, Miller NA, et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 2011; 3: 65ra4
82. Sikkema-Raddatz B, Johansson LF, de Boer EN, et al. Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Hum Mutat 2013; 34: 1035-1042
83. Linderman MD, Brandt T, Edelmann L, et al. Analytical validation of whole exome and whole genome sequencing for clinical applications. BMC Med Genomics 2014; 7: 20
84. Brownstein CA, Beggs AH, Homer N, et al. An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biol 2014; 15: R53
85. Weiss MM, Van Der Zwaag B, Jongbloed JD, et al. Best practice guidelines for the use of next-generation sequencing applications in genome diagnostics: a national collaborative study of Dutch genome diagnostic laboratories. Hum Mutat 2013; 34: 1313-1321
86. Peterlin B, Vidmar L, Borry P, et al. Expanded carrier screening tests currently on the commercial market. Eur J Hum Genet 2014; 22(Suppl 1): 291
87. Kingsmore S. Comprehensive carrier screening and molucular diagnostic testing for recessive childhood diseases. PLoS Curr 2012; e4f9877ab8ffa9
88. Orphanet. Prevalence and incidence of rare diseases: Bibilographic data. Orphanet Report Series 2015, http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence-of- rare-diseases-by-decreasing-prevalence-or-cases.pdf Last accessed 18 August 2015
89. Lazarin GA, Haque IS, Nazareth S, et al. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. Genet Med 2013; 15: 178-186
90. Francioli LC, Menelaou A, Puli SL, et al. Whole-genome sequence variation, population structure and demographic history of the Dutch population. Nat Genet 2014; 46: 818-825
91. Stenson PD, Mort M, Ball EV, et al. The Human Gene Mutation Database: 2008 update. Genome Med 2009; 1: 13
92. Borry P, Henneman L, Lakeman P, Ten Kate LP, Cornel MC, Howard HC. Preconceptional genetic carrier testing and the commercial offer directly-toconsumers. Hum Reprod 2011; 26: 972-977
93. European Association for the Study of the Liver: EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010; 53: 3-22
94. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 328-343
95. Dondorp W, De Wert G, Bombard Y, et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet 2015; 23: 1438-1450
96. Wertz DC, Knoppers BM. Serious genetic disorders: can or should they be defined? Am J Med Genet 2002; 108: 29-35
97. Lazarin GA, Hawthorne F, Collins NS, Platt EA, Evans EA, Haque IS. Systematic classification of disease severity for evaluation of expanded carrier screening panels. PLoS One 2014; 9: e114391
98. Anheim M, Elbaz A, Lesage S, et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012; 78: 417-420
99. Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med 2005; 7: 584-587
100. Schwartz B. The Paradox of Choice. Why More is Less. HarperCollins Publishers: New York, NY, USA, 2004
101. Elias S, Annas GJ. Generic consent for genetic screening. N Engl J Med 1994; 330: 1611-1613
102. Dondorp WJ, De Wert GM. The thousand-dollar genome : an ethical exploration. Eur J Hum Genet 2013; 21(Suppl 1): S6-S26
103. Hewison J. Psychological aspects of individualized choice and reproductive autonomy in prenatal screening. Bioethics 2015; 29: 9-18
104. Axworthy D, Brock DJ, Bobrow M, Marteau TM. Psychological impact of populationbased carrier testing for cystic fibrosis: 3-year follow-up. UK Cystic Fibrosis Follow-Up Study Group. Lancet 1996; 347: 1443-1446
105. Lakeman P, Plass AM, Henneman L, Bezemer PD, Cornel MC, Ten Kate LP. Three-month follow-up of Western and non-Western participants in a study on preconceptional ancestry-based carrier couple screening for cystic fibrosis and hemoglobinopathies in the Netherlands. Genet Med 2008; 10: 820-830
106. Ioannou L, Massie J, Collins V, McClaren B, Delatycki MB. Population-based genetic screening for cystic fibrosis: attitudes and outcomes. Public Health Genomics 2010; 13: 449-456
107. Mennie ME, Compton ME, Gilfillan A, et al. Prenatal screening for cystic fibrosis: psychological effects on carriers and their partners. J Med Genet 1993; 30: 543-548
108. Wald NJ. Couple screening for cystic fibrosis. Lancet 1991; 338: 1318-1319
109. Metcalfe S, Jacques A, Archibald A, et al. A model for offering carrier screening for fragile X syndrome to nonpregnant women: results from a pilot study. Genet Med 2008; 10: 525-535
110. Cousens NE, Gaff CL, Delatycki MB, Metcalfe SA. Prenatal beta-thalassemia carrier screening in Australia: healthcare professionals perspectives of clinical practice. Prenat Diagn 2014; 34: 246-250
111. Cousens N, Gaff C, Metcalfe S, Delatycki M. He didn t say that thalassaemia might come up. Beta-thalassaemia carriers experiences and attitudes. J Community Genet 2013; 4: 223-232
112. Marteau TM, van DM, Ellis I. Effects of genetic screening on perceptions of health: a pilot study. J Med Genet 1992; 29: 24-26
113. Henneman L, Bramsen I, Van Der Ploeg HM, Ten Kate LP. Preconception cystic fibrosis carrier couple screening: impact, understanding, and satisfaction. Genetic Testing 2002; 6: 195-202
114. Payne Y, Williams M, Cheadle J, et al. Carrier screening for cystic fibrosis in primary care: evaluation of a project in South Wales. The South Wales Cystic Fibrosis Carrier Screening Research Team. Clin Genet 1997; 51: 153-163
115. Gordon C, Walpole I, Zubrick SR, Bower C. Population screening for cystic fibrosis: knowledge and emotional consequences 18 months later. Am J Med Genet A 2003; 120A: 199-208
116. Raz AE, Vizner Y. Carrier matching and collective socialization in community genetics: Dor Yeshorim and the reinforcement of stigma. Soc Sci Med 2008; 67: 1361-1369
117. Markel H. The stigma of disease: implications of genetic screening. Am J Med 1992; 93: 209215
118. Kenen RH, Schmidt RM. Stigmatization of carrier status: social implications of heterozygote genetic screening programs. Am J Public Health 1978; 68: 1116-1120
119. Lakeman P, Henneman L, Bezemer PD, Cornel MC, Ten Kate LP. Developing and optimizing a decisional instrument using self-reported ancestry for carrier screening in a multi-ethnic society. Genet Med 2006; 8: 502-509
120. Delatycki MB, Wolthuizen M, Collins V, et al. IronXS: high-school screening for hereditary haemochromatosis is acceptable and feasible. Eur J Hum Genet 2012; 20: 505-509
121. Fears R, Ter Meulen VEASAC-FEAM Working Group: The perspective from EASAC and FEAM on direct-to-consumer genetic testing for health-related purposes. Eur J Hum Genet 2013; 21: 703-707